|1.||Mateo, Luis R: 10 articles (04/2013 - 01/2009)|
|2.||Zhang, Yun Po: 9 articles (06/2012 - 01/2009)|
|3.||DeVizio, William: 9 articles (06/2012 - 01/2009)|
|4.||Cummins, D: 9 articles (01/2011 - 01/2009)|
|5.||DeVizio, W: 7 articles (01/2012 - 01/2009)|
|6.||Zhang, Y P: 5 articles (01/2011 - 01/2009)|
|7.||Mateo, L R: 5 articles (01/2011 - 01/2009)|
|8.||Delgado, E: 5 articles (01/2011 - 01/2009)|
|9.||Cummins, Diane: 5 articles (05/2010 - 01/2009)|
|10.||Delgado, Evaristo: 4 articles (06/2012 - 03/2009)|
05/01/2013 - "The aim of this study was to evaluate the clinical efficacy of an in-office desensitizing paste containing 8% arginine and calcium carbonate relative to calcium carbonate alone in the reduction of dentin hypersensitivity in a randomized, double-blind, split-mouth clinical trial. "
02/01/2015 - "Efficacy of a combined in-office/home-use desensitizing system containing 8% arginine and calcium carbonate in reducing dentin hypersensitivity: an 8-week randomized clinical study."
06/01/2012 - "To evaluate the clinical efficacy of a professional prophylaxis paste containing 8% arginine-calcium carbonate in the reduction of dentin hypersensitivity used as a pre-procedural application compared to a commercially-available prophylaxis paste. "
06/01/2012 - "This paper provides an overview of the etiology of dentin hypersensitivity, the discovery and development of measures for combating the problem, and the available data on the clinical efficacy of products based on 8% arginine and calcium carbonate."
03/01/2009 - "Clinical evaluation of the efficacy of an in-office desensitizing paste containing 8% arginine and calcium carbonate in providing instant and lasting relief of dentin hypersensitivity."
07/01/2012 - "In Canada, first-line treatment of hyperphosphatemia consists primarily of calcium carbonate (CC). "
01/01/2015 - "An efficient, cost-effective, facile and commercially-viable formulation was demonstrated to deliver calcium carbonate for the treatment of hyperphosphatemia."
01/01/2015 - "Thus, phosphate binders such as calcium carbonate are commonly prescribed to CKD patients with hyperphosphatemia, but these have undesirable side effects. "
07/01/1998 - "Role of calcium carbonate administration timing in relation to food intake on its efficiency in controlling hyperphosphatemia in patients on maintenance dialysis."
09/01/1991 - "Calcium carbonate in hyperphosphatemia."
|3.||Hypercalcemia (Milk Alkali Syndrome)
11/01/1987 - "The efficacy of calcium carbonate (CaCO3) as a phosphate binder has been limited by its tendency to cause hypercalcemia. "
11/01/2013 - "Calcium carbonate intoxication in pregnancy: the return of the milk-alkali syndrome."
06/01/2013 - "An unwanted side effect of calcium carbonate is hypercalcemia and vascular calcification. "
10/01/2011 - "Evaluations for malignancy, thyroid, and parathyroid dysfunctions were non conclusive, therefore hypercalcemia in our patient was attributed to milk-alkali syndrome given the history of the prolonged calcium carbonate intake."
06/01/2011 - "Hypercalcemia was less frequent than with calcium carbonate. "
05/01/2013 - "The tested in-office desensitizing paste containing 8.0% arginine and calcium carbonate provides significantly greater hypersensitivity relief compared to calcium carbonate alone."
11/01/1981 - "Allergy to chalk dyes."
05/01/2013 - "Sixty teeth (30 subjects) with an air blast hypersensitivity score of 2 or 3 (Schiff Cold Air Sensitivity Scale) were randomly assigned to one of two treatment groups: (1) test paste containing 8% arginine and calcium carbonate (elmex sensitive professional desensitizing paste) and (2) control paste: paris white (calcium carbonate). "
04/01/2013 - "An air blast hypersensitivity score equal or greater to 2 (Schiff Cold Air Sensitivity Scale) was randomly assigned to one of two treatment groups (1) Pro-Relief in-office desensitizing fluoride-free paste containing 8% arginine and calcium carbonate (Test Paste group), and (2) a fluoride-free prophylaxis paste (Control Paste group). "
01/01/1998 - "Thus it can be concluded from this study that the use of a dentifrice containing 5.0% potassium nitrate and 1500 ppm sodium monofluorophosphate in a precipitated calcium carbonate (PCC) base is a clinically effective method for reducing dentinal hypersensitivity."
01/01/2013 - "The goal of this study is to describe secondary hyperparathyroidism in extremely low birthweight (ELBW) neonates and their response to enteral calcium carbonate (CaCO(3)) supplementation. "
01/01/1999 - "Secondary hyperparathyroidism in hemodialysis patients can often be reverted by oral calcium carbonate alone. "
06/01/1995 - "Thus, administration of 3 g oral calcium carbonate daily was highly effective in treating secondary hyperparathyroidism in patients with mild to moderate renal failure."
06/01/1995 - "We administered calcium carbonate orally to determine its safety and efficacy in treating nondialyzed patients with mild to moderate renal failure and secondary hyperparathyroidism. "
01/01/1998 - "Secondary hyperparathyroidism in severe chronic renal failure is corrected by very-low dietary phosphate intake and calcium carbonate supplementation."
|5.||fluorophosphate (sodium monofluorophosphate)
|6.||Sodium Fluoride (Ossin)
|9.||lanthanum carbonate (Fosrenol)
|1.||Renal Dialysis (Hemodialysis)
|2.||Continuous Ambulatory Peritoneal Dialysis (CAPD)
|5.||Lithotripsy (Extracorporeal Shockwave Lithotripsy)